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The human Ia region of the major histocompatibility complex (MHC) is composed 
of a  cluster  of genes  in  strong  linkage  disequilibrium  with  each  other,  coding  for 
molecules similar in structure expressed on the surface of B lymphocytes, macrophages, 
and T  cells, especially upon activation.  Since the first locus, DR, was recognized in 
the VII Histocompatibility Workshop, direct evidence has been obtained for at least 
two more loci, DC and BR, possessing genetic markers defined by specific alloantisera 
(1).  The  products  of the  DR  locus  are  the  predominant  species  of Ia  molecules, 
accounting for at least 60% of the Ia pool (2).  There is no doubt that DR molecules 
play a role in the mixed lymphocyte reaction (MLR)  (3).  Recent studies have shown 
that proliferation of T  cells can be strongly inhibited  by pretreatment of either the 
responder  T  cells  or  the  stimulating  cells  with  monoclonal  antibodies  specific  for 
products of the DR locus (4, 5). 
The  products  of the  DC  locus  constitute  a  smaller  fraction  of Ia molecules  (2). 
They have been shown both by microfingerprinting (6)  and by two-dimensional gel 
analysis (7) to differ from DR molecules in both subunits. These substantial structural 
differences suggested the possibility that  DC molecules could have functional  prop- 
erties distinct from those of DR molecules. The availability of a monoclonal antibody 
(MAb)  specifically directed  against  an allelic DC determinant,  DC1  (nomenclature 
equivalent  MB1,  MT1,  LB12),  a  DC determinant  in  strong linkage disequilibrium 
with DR1,2 and w6 (8), makes it possible to test this hypothesis. 
In this study we have investigated the effect of the anti DC1  MAb on MLR and 
other in vitro systems. We show here that, unlike anti-DR antibodies, anti-DC1  has 
no effect on cell proliferation. However, anti-DC 1 affects the generation of effector T 
cells mediating specific cytolytic activity, whereas no inhibitory effect can be observed 
on natural killer (NK) and antibody-dependent cytotoxic cell (ADCC) activities. 
Materials and Methods 
Monoclonal Antibodies.  Derivation of the MAb used in the present study has been previously 
described  (6,  9,  10). The  anti-DR  PTF29.12  is  an  IgG2  antibody  to  a  nonpolymorphic 
determinant of human DR molecules;  BT3/4 is an IgG1 antibody directed at a polymorphic 
determinant of DC molecules  present on the DC 1 allele  (6). The MAb were used in the form 
of purified IgG at a final concentration of 50 #g/ml unless otherwise specified. 
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Cell Cultures.  Peripheral blood mononuclear  cells (PBMC) were obtained from donors typed 
for  DR  and  DC1  as  previously described  (11). The  responding cell  population in  mixed 
lymphocyte culture (MLC) consisted either of PBMC or purified T  lymphocytes obtained by 
isolating lymphocytes forming rosettes with neuraminidase-treated  sheep erythrocytes (E-roset- 
ting cells) by two sequential centrifugations on Ficoll-Hypaque density gradients. T cells were 
freed  of erythrocytes  by  treatment  with  ammonium chloride  buffer.  The  stimulating cell 
population, consisting of either PBMC or E rosette-depleted cells, was irradiated with 4,500 rad 
using a Cesium source. Unidirectional  MLC were set up by culturing responding cells either in 
macrowells (10  ~  cells/well) or in round-bottomed microwells (105 cells/well) with equal numbers 
of irradiated allogeneic cells in RPMI 1640 containing 10% fetal calf serum (FCS) as previously 
described (11). Control samples included responding or stimulating cells cultured alone. MAb 
were added at the onset of the culture, unless otherwise specified,  at a dose of 5/~g/well, in the 
case of microcultures, or at a dose of 50 ~g/well, when MLC were set up in macrowells. Cell 
proliferation and cytotoxicity were assessed on day 7 as previously described (12). Briefly,  to 
evaluate cell  proliferation, tritiated thymidine ([3H]TdR)  was added to triplicate microwell 
cultures 18 h before harvesting. Cytolytic assays were performed against (a) phytohemagglutinin 
(PHA)- induced blasts derived from the stimulator cell population, (b) K 562 cell line, and (c) 
antibody-coated murine L  1210 tumor cells. Varying numbers (37.5  ×  104 to 5  ×  l0  s)  of T 
lymphocytes were incubated in V-bottomed wells of microtiter trays with 5 ×  10  a 51Cr-labeled 
target cells at a  final volume of 200/~1, thus ensuring lymphocyte/target cell  ratios ranging 
from 7.5:1 to  100:1. The microplates were centrifuged at  100 g for 7 min. Cytolysis was then 
assessed by counting the radioactivity of 0.1 ml supernatant for 1 min in a scintillation  counter. 
Specific lysis was calculated according to Cerottini et al.  (13). Pokeweed mitogen (PWM) and 
tetanus toxoid stimulation were performed as previously described (11). 
Results and Discussion 
Unidirectional MLC were set up, to which BT3.4 (anti DC 1)  MAb was added at 
the onset of culture. It should be noted that either the responder or the stimulating 
cell population was DC 1 positive. As BT3.4 is specific for that allele of the DC locus, 
this ensured that the antibody could react with the responder or the stimulating cell 
population, but not with both. 
As shown in Table I, in no instance did the presence of the anti-DC 1 Mab inhibit 
T  cell  proliferation.  Under  the  same  experimental  conditions, an  anti-DR  MAb 
TABLE  I 
Effect of Addition of Anti-DC1  (BT3.4) and Anti-DR (PTF29.12) MAb on 
Proliferative Response in MLC 
Experiment  R  S  Antibody added  [3H]TdR 
Number 
cpm 
1  DR 2,w6 DC1 ÷  DR 5 DC1-  None  57,993  +_  1,425" 
BT3.4  46,837  ±  684 
PTF29.12  4,850 +_ 720 
2  DR 2,w6 DCI +  DR 4,5 DC1  None  52,325  +- 3,198 
BT3.4  60,102  +  1,426 
3  DR  1,2 DCI ÷  DR 5 DCI-  None  74,390  ±  2,492 
BT3.4  67,853  ±  2,880 
4  DR 2,w6 DC1 +  DR 3,7 DCI-  None  56,098  +  1,163 
BT3.4  51,918  ±  1,022 
5  DR 3,5 DC1-  DR  1,2 DC1 +  None  58,344  +_ 2,802 
BT3.4  57,690  ±  1,867 
6  DR 5 DC1-  DR 2,w6 DCI +  None  45,933  +  2,518 
BT3.4  44,878  --_ 2,518 
PTF29.12  4,635  +  600 
* Values  are  expressed  as  mean  cpm  ±  SD  of triplicate  cultures  after  having subtracted  background  counts  due  to 
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reduced [3H]TdR uptake to < 10% the control value. Thus, unlike anti-DR antibodies, 
anti-DC1  does not interfere with T  cell proliferation in MLC. Only one experiment 
is reported for the anti-DR MAb, as it reacts against a nonpolymorphic determinant 
of DR  molecules and  hence its effect is  independent of the phenotype of the cell. 
Effector T  cells are generated during MLC  that  are responsible for the lysis of (a) 
PHA-induced  blast  cells bearing  the  stimulating  alloantigens,  (b)  K562  erythroid 
tumor  line  (nonspecific  killing  or  NK-like),  and  (c)  antibody-coated  target  cells 
(ADCC activity). We have investigated whether the anti-DC 1 MAb had any effect 
on these various cytolytic activities. As shown in Figs.  1 and 2, when the effector cells 
were  derived from  MLC  in  which  BT3.4  MAb  was  added  from  the  onset  of the 
culture, a marked difference in terms of specific cytolytic activity (CTL) was observed, 
depending upon the phenotype of the donors used. In fact, when the responding cells 
were DC 1 negative and the stimulating cells DC 1 positive (Fig. 1), no difference could 
be observed between the specific effector T  cells generated in such combination and 
those obtained from control cultures to which BT3.4 was not added. 
On  the  other  hand,  when  the  reverse  combination  was  used  (responder  DC1 
positive, stimulator DC 1 negative), those activated T  cells generated were virtually 
devoid of CTL activity. No differences were observed in between the combinations in 
terms of effector cells capable of killing in ADCC- or in NK-like activity (data not 
shown). Furthermore, the addition of BT3.4 directly to the cytolytic test could, at this 
stage,  affect neither  the  specific cytolytic activity of DCl-positive  effector T  cells 
generated in MLC nor the killing of DC 1-positive target cells (data not shown). 
To  check whether  the  anti-DC1  antibody  had  any  effect on  proliferation  to  a 
soluble antigen or on B cell differentiation, PBMC  from DC 1-positive donors were 
stimulated in culture with optimal concentrations of PWM or tetanus toxoid in the 
presence and  in the absence of the MAb.  Proliferation was evaluated by [aH]TdR 
uptake, and B cell differentiation was determined by the number of cytoplasmic Ig 
(cIg)  -positive cells  stained  by  a  fluoroscein isothiocyanate  (FITC)  :coupled  anti- 
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FXG.  l.  Specific CTL activity of DCl-negative T  cell populations activated in MLC. T  cells were 
cultured for 7 d in allogeneic MLC, and thereafter their cytolytic activity against the PHA-activated 
ceils hearing the stimulating alloantigens was tested.  From  left to  right:  experiments 5  and 6  of 
Table I. Untreated control (0); MLC treated with BT3/4 (A). 100. 
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Fro. 2.  Specific CTL activity of DCl-positive T cell populations activated in MLC. From top left 
to bottom right: experiments  1, 2, 3, and 4 of Table I. Untreated control (0); MLC treated with 
BT3/4 (A). 
human  Ig antibody and the amount  of Ig secreted in the culture fluid. As shown  in 
Table  II,  the  presence  of BT3.4  reduced  neither  proliferation,  the  number  of cIg 
positive cells, nor the amount of secreted Ig, whereas the anti-DR antibody abolished 
the response to both PWM  and the soluble antigen (data not shown). 
The above results show that  in in vitro systems the effect of an antibody directed 
against a product of the DC locus is quite different from that of an antibody directed 
against a product of the DR locus. Thus, proliferation of T  cells, or at least of most of 
them,  is not  disturbed by the anti-DC1  antibody, whereas unmasked  DC  molecules 
seem  to  be  essential  for  proliferation  and/or  differentiation  of CTL  precursors  in 
MLC. At this stage, however, it is impossible to tell whether these cells are blocked by 
a  negative signal generated by the interaction of the antibody with membrane  DC 1 
or  because  masking  of  the  molecule  prevents  recognition  of  the  allogeneic  cell. 
Nevertheless, it is clear that DC molecules are neither receptors nor target molecules 
necessary for lysis of the target cells, as shown  by the lack of effect of the antibody CORTE  ET  AL.  BRIEF DEFINITIVE REPORT 
TABLE II 
Effect of Addition of Anti-DC1  (BT3.4) and Anti-DR (PTF29.12) MAb 
on PWM and Tetanus Toxoid stimulation 
PWM 
Antibody added  elg  + cells/lO  6 cells  Secreted  Ig 
None  160,000  700 =1:107 
BT3.4  115,000  630 +  53 
PTF29.12  25,000  150 +_ 26 
Tetanus Toxoid 
[ S  H] TdR uptake* 
None  24,280  _+  1,561 
Bt3.4  22,630  +  1,312 
* Values are expressed as mean cpm +- SD of triplicate cultures  after having subtracted 
background counts due to PBMC cultured  alone. 
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added directly to  the  cytolytic test.  Taken  together,  the  above results indicate that 
DC  molecules are not only, as previously shown  (6), structurally different from DR 
molecules,  but  also  that  they  play  distinct  functions  on  the  surface  of B  and  T 
lymphocytes. 
Summary 
The  products of the  DC  locus have been shown  to be structurally different  from 
those of the  DR  locus.  In this paper it is shown  that,  unlike anti-DR  antibodies, a 
monoclonal antibody directed against DC 1 does not affect proliferation of T  cells in 
response  to  alloantigens  or  soluble  antigens  or  production  of  Ig  in  a  pokeweed 
mitogen-stimulated in vitro culture. However, the anti-DC 1 inhibits the generation of 
effector T  cells mediating specific cytolytic activity, whereas no inhibitory effect can 
be observed on natural killer and antibody-dependent cytotoxic cell activities. 
Received  for publication 26July 1982. 
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